Browsing Tag

Michael J. Parini

Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the…

Eli Pacheco Jan 28, 2022 0

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative…

Health

Freeline Announces 2022 Corporate Priorities and Guidance

Eli Pacheco Dec 14, 2021 0

Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated…